Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02685995 · ClinicalTrials.gov registry record · NA

VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC

A NA study of Renal Failure Chronic Requiring Hemodialysis and Chronic Renal Insufficiency, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
100
Enrollment target
2
Study locations

NCT02685995 is a NA study of Renal Failure Chronic Requiring Hemodialysis and Chronic Renal Insufficiency that has completed, run by University of Pennsylvania. The registered enrollment target is 100 participants, above the 23-participant average among 3 other Renal Failure Chronic Requiring Hemodialysis trials with a reported enrollment target (335% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02685995, a NA study of Renal Failure Chronic Requiring Hemodialysis and Chronic Renal Insufficiency, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

Randomized two-arm study examining 90 day primary patency of two FDA-approved tunneled dialysis catheters.

Interventions

  • DEVICE VectorFlow TDC
  • DEVICE Palindrome TDC

Study Locations (2)

Pennsylvania

  • Hospital of the Unviersity of Pennsylvania - Philadelphia
  • Penn Presbyterian Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2015-12
Est. Completion 2020-07
Phase NA

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02685995

The ClinicalTrials.gov registry entry for NCT02685995 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 23-participant average among 3 other Renal Failure Chronic Requiring Hemodialysis trials with a reported enrollment target (335% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Renal Failure Chronic Requiring Hemodialysis appearing as the primary indexed condition, and to 2 interventions - of which VectorFlow TDC is the first listed.

NCT02685995 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02685995 about?

NCT02685995 is a clinical study titled "VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC". Randomized two-arm study examining 90 day primary patency of two FDA-approved tunneled dialysis catheters.

What is the current status of trial NCT02685995?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2015-12. Estimated completion is 2020-07.

What conditions does trial NCT02685995 study?

This clinical trial studies the following conditions: Renal Failure Chronic Requiring Hemodialysis, Chronic Renal Insufficiency.

What interventions are being tested in trial NCT02685995?

The interventions under investigation include: VectorFlow TDC (DEVICE), Palindrome TDC (DEVICE).

Who is sponsoring clinical trial NCT02685995?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02685995 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Renal Failure Chronic Requiring Hemodialysis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.